Association of moderately abnormal behavior and administered neuraminidase inhibitors

Drug Discov Ther. 2020 Mar 8;14(1):50-53. doi: 10.5582/ddt.2019.01091. Epub 2020 Feb 26.

Abstract

Our earlier study investigated the incidence of severe abnormal behavior associated with neuraminidase inhibitors (NIs), but some studies have specifically examined the association of oseltamivir use and moderately abnormal behavior. Therefore, this study was undertaken to assess associations between moderately abnormal behavior and administered drugs. All cases of patients with influenza who exhibited moderately abnormal behavior were reported to us by physicians of all sentinel clinics and hospitals for influenza throughout Japan. Open Data of the National Database of Electronic Medical Claims include the numbers of patients diagnosed as having influenza who were prescribed NI. Incidence by NI was tested using Fisher's exact test. We received 518 moderately abnormal cases in 5-9-year-olds and 207 moderately abnormal behavior cases in 10-19-year-olds. The incidence among NI ranged from 193 per one million influenza patients in laninamivir among 10-19-year-olds to 1021 for peramivir among 5-9-year-olds. Estimation results revealed the order of risk among NIs as peramivir, oseltamivir, zanamivir and laninamivir in moderate abnormal behavior. Because of data limitations, risk among patients with and without NI cannot be compared.

Keywords: Moderately abnormal behavior; incidence; influenza; neuraminidase inhibitors; relative risk.

MeSH terms

  • Acids, Carbocyclic
  • Adolescent
  • Antiviral Agents / administration & dosage
  • Antiviral Agents / adverse effects
  • Child
  • Cyclopentanes / administration & dosage
  • Cyclopentanes / adverse effects
  • Enzyme Inhibitors / administration & dosage
  • Enzyme Inhibitors / adverse effects*
  • Guanidines / administration & dosage
  • Guanidines / adverse effects
  • Humans
  • Illness Behavior / drug effects*
  • Influenza, Human / drug therapy*
  • Influenza, Human / psychology*
  • Japan
  • Neuraminidase / antagonists & inhibitors*
  • Oseltamivir / administration & dosage
  • Oseltamivir / adverse effects
  • Pyrans
  • Sialic Acids
  • Young Adult
  • Zanamivir / administration & dosage
  • Zanamivir / adverse effects
  • Zanamivir / analogs & derivatives

Substances

  • Acids, Carbocyclic
  • Antiviral Agents
  • Cyclopentanes
  • Enzyme Inhibitors
  • Guanidines
  • Pyrans
  • Sialic Acids
  • Oseltamivir
  • laninamivir
  • Neuraminidase
  • Zanamivir
  • peramivir